Histamine regulates growth of malignant melanoma implants via H2 receptors in mice

Inflammopharmacology

Volumn 13, Issue 1-3, 2005, Pages 281-289

  Tomita, Kazuyoshi ^a   Nakamura, Eiji ^a   Okabe, Susumu ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

B16BL6; Cell proliferation; Cimetidine; H2 receptor antagonist; Roxatidine; Tumor growth

Indexed keywords

CIMETIDINE; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; MESSENGER RNA; NITROBLUE TETRAZOLIUM; ROXATIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; HISTAMINE RELEASE; MALE; MELANOMA CELL; MOUSE; MOUSE STRAIN; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CIMETIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HISTAMINE; HISTAMINE AGENTS; HISTAMINE H2 ANTAGONISTS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PIPERIDINES; RECEPTORS, HISTAMINE H2; RNA, MESSENGER;

EID: 27744475082     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856005774423917     Document Type: Article

References (14)

1. Darvas, Z., Sakurai, E., Schwelberger, H. G., et al. (2003). Autonomous histamine metabolism in human melanoma cells, Melanoma Res. 13, 239-246.
2. Donskov, F., Bennedsgaard, K. M., Hokland, M., et al. (2004). Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma, Cancer Immunol. Immunother. 53, 729-739.
3. Falus, A., Hegyesi, H., Lazar-Molnar, E., et al. (2001). Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation, Trends Immunol. 22, 648-652.
4. Haak-Frendscho, M., Darvas, Z., Hegyesi, H., et al. (2000). Histidine decarboxylase expression in human melanoma, J. Invest. Dermatol. 115, 345-352.
5. Hegyesi, H., Somlai, B., Varga, V. L., et al. (2001). Suppression of melanoma cell proliferation by histidine decarboxylase specific antisense oligonucleotides, J. Invest. Dermatol. 117, 151-153.
6. Hellstrand, K. (2002). Histamine in cancer immunotherapy: a preclinical background, Semin. Oncol. 29, 35-40.
7. Janik, P., Briand, P. and Hartmann, N. R. (1975). The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors, Cancer Res. 35, 3698-3704.
8. Jorkov, A. S., Donskov, F., Steiniche, T., et al. (2003). Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride, Anticancer Res. 23, 537-542.
9. Kono, K., Salazar-Onfray, F., Petersson, M., et al. (1996). Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity, Eur. J. Immunol. 26, 1308-1313.
10. Lindner, P., Rizell, M., Mattsson, J., et al. (2004). Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma, Anticancer Res. 24, 1837-1842.
11. Molnar, E. L., Cricco, G., Martin, G., et al. (2001). Histamine as a potential autocrine regulator of melanoma, Inflamm. Res. 50 (Suppl. 2), S102-S103.
12. Reynolds, J. L., Akhter, J. and Morris, D. L. (1996). In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines, Melanoma Res. 6, 95-99.
13. Tomita, K., Izumi, K. and Okabe, S. (2003). Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice, J. Pharmacol. Sci. 93, 321-330.
14. Tomita, K. and Okabe, S. (2005). Exogenous histamine stimulates colorectal cancer implant growth via immunosuppression in mice, J. Pharmacol. Sci. 97, 116-123.